383870-88-0

Basic information

• Product Name: 2-methoxy-5-morpholinoaniline
• Synonyms: 2-methoxy-5-morpholinoaniline;Benzenamine, 2-methoxy-5-(4-morpholinyl)-
• CAS NO: 383870-88-0
• Molecular Formula: C₁₁H₁₆N₂O₂
• Molecular Weight: 208.25694
• Mol File: 383870-88-0.mol
• Article Data: 9

Chemical Properties

• Boiling Point: 412.5±45.0 °C(Predicted)
• Appearance: /
• Density: 1.163±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 5.96±0.40(Predicted)
• CAS DataBase Reference: 2-methoxy-5-morpholinoaniline(CAS DataBase Reference)
• NIST Chemistry Reference: 2-methoxy-5-morpholinoaniline(383870-88-0)
• EPA Substance Registry System: 2-methoxy-5-morpholinoaniline(383870-88-0)

Safety Data

• Hazardous Substances Data: 383870-88-0(Hazardous Substances Data)

Usage

General Description

2-methoxy-5-morpholinoaniline is a chemical compound with the chemical formula C9H12N2O2. It is an organic compound that contains a methoxy group and a morpholino group, along with an aniline moiety. 2-methoxy-5-morpholinoaniline is commonly used in the pharmaceutical industry as an intermediate for the synthesis of various pharmaceutical drugs. It has also been studied for its potential biological activities, including its anti-inflammatory and anticancer properties. 2-methoxy-5-morpholinoaniline is considered to be a valuable building block in the development of new drug molecules due to its unique structure and potential medicinal properties.

Upstream product

• 955095-74-6 4-(4-methoxyhenyl)morpholine nitric acid salt 
• 104-94-9 4-methoxy-aniline 
• 383870-96-0 4-(4-methoxy-3-nitrophenyl)morpholine 
• 33696-00-3 4-bromo-1-methoxy-2-nitrobenzene 

Downstream Products

• 383870-59-5 (2-methoxy-5-morpholin-4-yl-phenyl)thiourea 
• 870070-55-6 Tozadenant 
• 383869-80-5 phenyl (4-methoxy-7-morpholin-4-yl-benzo[d]thiazol-2-yl)carbamate 
• 383865-57-4 4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl-amine 
• 700809-92-3 N₃-(2-methoxy-5-morpholin-4-yl-phenyl)-1-pyridin-2-yl-1H-[1,2,4]triazoIe-3,5-diamine 
• 1253380-03-8 1-[(2-chloro-4-fluorophenyl)methyl]-4-[2-(methyloxy)-5-(4-morpholinyl)phenyl]-2,3-piperazinedione 
• 796061-71-7 1H-imidazole-2-carboxylic acid (2-methoxy-5-morpholin-4-yl-phenyl)-amide 
• 796061-74-0 1H-benzoimidazole-2-carboxylic acid (2-methoxy-5-morpholin-4-yl-phenyl)-amide 
• 383870-86-8 1-benzoyl-3-(2-methoxy-5-morpholin-4-yl-phenyl)thiourea 
• 538327-36-5 N-(2-methoxy-5-morpholin-4-yl-phenyl)-oxalamic acid ethyl ester 

Relevant articles and documents

Design, synthesis and biological evaluation of Tozadenant analogues as adenosine A2A receptor ligands

With the aim to obtain potent adenosine A2A receptor (A2AR) ligands, a series of eighteen derivatives of 4-hydroxy-N-(4-methoxy-7-morpholin-4-yl-1,3-benzo[d]thiazol-2-yl)-4-methylpiperidine-1-carboxamide (SYN-115, Tozadenant) were designed and synthesized. The target compounds were obtained by a chemical building block principle that involved reaction of the appropriate aminobenzothiazole phenyl carbamates with either commercially available or readily synthesized functionalized piperidines. Their affinity and subtype selectivity with regard to human adenosine A1-and A2A receptors were determined using radioligand binding assays. Ki values for human A2AR ranged from 2.4 to 38 nM, with more than 120-fold selectivity over A1 receptors for all evaluated compounds except 13k which had a Ki of 361 nM and 18-fold selectivity. The most potent fluorine-containing derivatives 13e, 13g and 13l exhibited Ki values of 4.9 nM, 3.6 nM and 2.8 nM for the human A2AR. Interestingly, the corresponding values for rat A2AR were found to be four to five times higher. Their binding to A2AR was further confirmed by radiolabeling with 18F and in vitro autoradiography in rat brain slices, which showed almost exclusive striatal binding and complete displacement by the A2AR antagonist ZM 241385. We conclude that these compounds represent potential candidates for the visualization of the A2A receptor and open pathways to novel therapeutic treatments of neurodegenerative disorders or cancer.

Discovery of novel 5-fluoro-N2,N4-diphenylpyrimidine-2,4-diamines as potent inhibitors against CDK2 and CDK9

Based on a 3D-QSAR pharmacophore derived from a diverse set of known cyclin-dependent kinase 9 (CDK9) inhibitors and a composite pharmacophore extracted from the complex structure of flavopiridol (FVP)-CDK9, thirty novel 5-fluoro-N2,N4-diphenylpyrimidine-2,4-diamine derivatives were designed and synthesized. Initial tests against four tumor cell lines with the sulforhodamine B (SRB) assay identified a series of potent compounds with GI50 values at a lower micromolar or submicromolar level. Most of the highly cytotoxic compounds exhibited potent inhibitory activities against both CDK2/cyclin E1 and CDK9/cyclin T1. Notably, inhibitions against the two enzymes were generally correlated well with the cytotoxicity of these compounds. Appreciable inhibition was also observed for selected compounds in the anti-HIV-1 assay. Docking studies on compounds 6d and 9g provided conducive clues to further structural optimization. This journal is

NOVEL COMPOUNDS 515

There is provided novel pyrimidine derivatives of formula (I) or pharmaceutically acceptable salts thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy